Literature DB >> 6436393

Protection against infection with Pseudomonas aeruginosa by passive transfer of monoclonal antibodies to lipopolysaccharides and outer membrane proteins.

S Sawada, M Suzuki, T Kawamura, S Fujinaga, Y Masuho, K Tomibe.   

Abstract

Experimental infection with Pseudomonas aeruginosa was treated with eight different monoclonal antibodies (MCAs) produced by hybridoma cells obtained through cell fusion of mouse plasmacytoma cells and spleen cells from mice immunized with a virulent strain of P. aeruginosa (Homma serotype 7). Five MCAs bound to lipopolysaccharides (LPSs) specific to serotype 7 or serotypes 2, 7, and 13, whereas the other three MCAs bound with broad specificities to outer membrane protein (OMP) fractions. The MCAs to LPS were highly protective against infection, with 50% protective doses of 0.05-2.5 micrograms of immunoglobulin per mouse. In contrast, the MCAs to OMP were much less protective, with a 50% protective dose range of 10 to greater than 100 micrograms of immunoglobulin per mouse. Most of the MCAs to LPS agglutinated P. aeruginosa cells, but all the MCAs to OMP produced so far have not, although all the MCAs bound well to the cells. Agglutinating MCAs provided better protection than did nonagglutinating MCAs.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6436393     DOI: 10.1093/infdis/150.4.570

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  22 in total

1.  Polyclonal and monoclonal antibody therapy for experimental Pseudomonas aeruginosa pneumonia.

Authors:  J E Pennington; G J Small; M E Lostrom; G B Pier
Journal:  Infect Immun       Date:  1986-10       Impact factor: 3.441

2.  Pseudomonas aeruginosa immunotherapy.

Authors:  J E Pennington
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1990-06       Impact factor: 3.267

3.  Functionally active monoclonal antibody that recognizes an epitope on the O side chain of Pseudomonas aeruginosa immunotype-1 lipopolysaccharide.

Authors:  B J Stoll; M Pollack; L S Young; N Koles; R Gascon; G B Pier
Journal:  Infect Immun       Date:  1986-09       Impact factor: 3.441

4.  Structural analysis and immunogenicity of Pseudomonas aeruginosa immunotype 2 high molecular weight polysaccharide.

Authors:  G B Pier; S E Bennett
Journal:  J Clin Invest       Date:  1986-02       Impact factor: 14.808

5.  Smooth lipopolysaccharide is the major protective antigen for mice in the surface extract from IATS serotype 6 contributing to the polyvalent Pseudomonas aeruginosa vaccine PEV.

Authors:  S MacIntyre; R Lucken; P Owen
Journal:  Infect Immun       Date:  1986-04       Impact factor: 3.441

Review 6.  Perspectives on the potential for successful development of outer membrane protein vaccines.

Authors:  H E Gilleland; J M Matthews-Greer
Journal:  Eur J Clin Microbiol       Date:  1987-06       Impact factor: 3.267

7.  Mechanisms of specific immunological unresponsiveness to bacterial lipopolysaccharides.

Authors:  K L Elkins; P W Stashak; P J Baker
Journal:  Infect Immun       Date:  1987-12       Impact factor: 3.441

8.  Protection against Brucella abortus in mice with O-polysaccharide-specific monoclonal antibodies.

Authors:  J A Montaraz; A J Winter; D M Hunter; B A Sowa; A M Wu; L G Adams
Journal:  Infect Immun       Date:  1986-03       Impact factor: 3.441

9.  Phage display and bacterial expression of a recombinant Fab specific for Pseudomonas aeruginosa serotype O6 lipopolysaccharide.

Authors:  N L Tout; J S Lam
Journal:  Clin Diagn Lab Immunol       Date:  1997-03

10.  Human monoclonal antibodies that protect mice against challenge with Pseudomonas aeruginosa.

Authors:  H J Zweerink; M C Gammon; C F Hutchison; J J Jackson; D Lombardo; K M Miner; J M Puckett; T J Sewell; N H Sigal
Journal:  Infect Immun       Date:  1988-08       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.